SCHEMBL22495435

SCHEMBL22495435

COc1ccc(C(=O)Nc2ccc(N3CCN(c4ccc(C#N)nc4)CC3)cc2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.52
KMT2A Q03164 8/20 0.52
ALDH1A1 P00352 7/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
MEN1 O00255 6/20 0.52
HSD17B10 Q99714 3/20 0.52
HPGD P15428 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
RXFP1 Q9HBX9 2/20 0.52
RAB9A P51151 5/20 0.51
NPC1 O15118 3/20 0.51
NR4A1 P22736 1/20 0.50
MCL1 Q07820 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.47
LMNA P02545 2/20 0.47
QSOX1 O00391 1/20 0.47
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.46
KDM4E B2RXH2 1/20 0.46
P4HTM Q9NXG6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31504237 1.00 MAPT (0.52) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL31504240 0.89 MAPT (0.53) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL22495468 0.89 MAPT (0.53) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL22495199 0.88 RAB9A (0.67) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL31504245 0.88 RAB9A (0.67) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL22495282 0.84 PANK3 (0.52) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL31504260 0.84 PANK3 (0.52) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL22495254 0.82 MAPT (0.53) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL22495216 0.79 LMNA (0.58) MAPTKMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL31504198 0.79 LMNA (0.58) MAPTKMT2AALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3728234-B1 RADIOLABELED COMPOUNDS HOFFMANN LA ROCHE (CH) 2025-05-14 EP claimed
US-11541132-B2 Radiolabeled compounds HOFFMANN-LA ROCHE INC. (US) 2023-01-03 US claimed
US-20200316232-A1 RADIOLABELED COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-10-08 US claimed
CN-111511732-A Radiolabelled compounds 豪夫迈·罗氏有限公司 2020-08-07 CN claimed
EP-3728234-B1 RADIOLABELED COMPOUNDS HOFFMANN LA ROCHE (CH) 2025-05-14 EP disclosed
US-11541132-B2 Radiolabeled compounds HOFFMANN-LA ROCHE INC. (US) 2023-01-03 US disclosed
US-11541132-B2 Radiolabeled compounds HOFFMANN-LA ROCHE INC. (US) 2023-01-03 US disclosed
US-20200316232-A1 RADIOLABELED COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-10-08 US disclosed
US-20200316232-A1 RADIOLABELED COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-10-08 US disclosed
CN-111511732-A Radiolabelled compounds 豪夫迈·罗氏有限公司 2020-08-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541132-B2 Radiolabeled compounds SNCA, APP, BACE1 MAPT 16/4885KMT2A 4463/4885ALDH1A1 1769/4885
US-20200316232-A1 RADIOLABELED COMPOUNDS SNCA, APP, BACE1 MAPT 17/4885KMT2A 4496/4885ALDH1A1 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.